FibroGen, Inc (NASDAQ:FGEN) VP Pat Cotroneo sold 2,851 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $49.45, for a total transaction of $140,981.95. Following the completion of the sale, the vice president now owns 157,405 shares of the company’s stock, valued at $7,783,677.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Pat Cotroneo also recently made the following trade(s):

  • On Tuesday, August 8th, Pat Cotroneo sold 95,000 shares of FibroGen stock. The shares were sold at an average price of $50.61, for a total transaction of $4,807,950.00.
  • On Wednesday, August 2nd, Pat Cotroneo sold 28,346 shares of FibroGen stock. The shares were sold at an average price of $33.97, for a total transaction of $962,913.62.
  • On Thursday, July 6th, Pat Cotroneo sold 4,000 shares of FibroGen stock. The shares were sold at an average price of $34.00, for a total transaction of $136,000.00.
  • On Thursday, June 22nd, Pat Cotroneo sold 3,000 shares of FibroGen stock. The shares were sold at an average price of $32.00, for a total transaction of $96,000.00.
  • On Monday, June 19th, Pat Cotroneo sold 5,500 shares of FibroGen stock. The shares were sold at an average price of $30.00, for a total transaction of $165,000.00.

FibroGen, Inc (NASDAQ FGEN) opened at 52.40 on Friday. FibroGen, Inc has a 12 month low of $15.60 and a 12 month high of $52.70. The firm’s 50-day moving average is $43.31 and its 200-day moving average is $32.07. The firm’s market capitalization is $3.73 billion.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The business had revenue of $29.00 million during the quarter, compared to analyst estimates of $34.80 million. FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. On average, equities research analysts expect that FibroGen, Inc will post ($1.80) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “FibroGen, Inc (FGEN) VP Sells $140,981.95 in Stock” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2017/09/16/fibrogen-inc-fgen-vp-sells-140981-95-in-stock.html.

A number of equities research analysts recently issued reports on FGEN shares. Citigroup Inc. restated a “buy” rating and issued a $48.00 target price on shares of FibroGen in a report on Monday, June 26th. Jefferies Group LLC restated a “buy” rating and issued a $75.00 target price on shares of FibroGen in a report on Tuesday. Leerink Swann restated an “outperform” rating and issued a $82.00 target price (up from $52.00) on shares of FibroGen in a report on Tuesday, August 8th. BidaskClub upgraded shares of FibroGen from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. Finally, Goldman Sachs Group, Inc. (The) downgraded shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 target price for the company. in a report on Friday, July 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $60.17.

Institutional investors and hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. acquired a new position in shares of FibroGen in the 1st quarter valued at about $111,000. Quantbot Technologies LP acquired a new position in shares of FibroGen in the 2nd quarter valued at about $128,000. SG Americas Securities LLC increased its holdings in shares of FibroGen by 6.5% in the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 412 shares during the period. Airain ltd acquired a new position in shares of FibroGen in the 1st quarter valued at about $236,000. Finally, Amalgamated Bank acquired a new position in shares of FibroGen in the 2nd quarter valued at about $237,000. Institutional investors own 47.49% of the company’s stock.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.